BVF PARTNERS L P/IL - 15 May 2025 Form 4 Insider Report for Allakos Inc. (ALLK)

Reporting relationship: 10%+ Owner
Issuer ticker: ALLK
Reported as of: 15 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2025, 18:45:29 UTC
Prior SEC filing: 28 Jan 2025
Next SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President

Key filing fact

BVF PARTNERS L P/IL filed Form 4 for Allakos Inc. (ALLK) on 19 May 2025.

Key facts

This page summarizes BVF PARTNERS L P/IL's Form 4 filing for Allakos Inc. (ALLK).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2025, 18:45.

Change

Previous filing in this sequence was filed on 28 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (10)

CIK 0001055947 Primary reporting owner

BVF PARTNERS L P/IL

Relationship: 10%+ Owner
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date: 19 May 2025

CIK 0000918923

BIOTECHNOLOGY VALUE FUND L P

Relationship: Other*
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 19 May 2025

CIK 0001803805

BVF I GP LLC

Relationship: Other*
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 19 May 2025

CIK 0001102444

BIOTECHNOLOGY VALUE FUND II LP

Relationship: Other*
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 19 May 2025

CIK 0001803806

BVF II GP LLC

Relationship: Other*
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 19 May 2025

CIK 0001660683

Biotechnology Value Trading Fund OS LP

Relationship: Other*
Address: P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS
Signature: BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date: 19 May 2025

CIK 0001660684

BVF Partners OS Ltd.

Relationship: Other*
Address: P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS
Signature: Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date: 19 May 2025

CIK 0001803809

BVF GP HOLDINGS LLC

Relationship: 10%+ Owner
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date: 19 May 2025

CIK 0001056807

BVF INC/IL

Relationship: 10%+ Owner
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: BVF Inc., By: /s/ Mark N. Lampert, President
Signature date: 19 May 2025

CIK 0001233840

LAMPERT MARK N

Relationship: 10%+ Owner
Address: 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature: /s/ Mark N. Lampert
Signature date: 19 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLK transaction

Common Stock, $0.001 par value

Disposed to Issuer

Transaction value
Shares: -8,679,726
Change %: -100%
Price
Shares after: 0
Date: 15 May 2025
Ownership: Direct
Footnotes: F1, F2, F3

ALLK transaction

Common Stock, $0.001 par value

Disposed to Issuer

Transaction value
Shares: -6,777,935
Change %: -100%
Price
Shares after: 0
Date: 15 May 2025
Ownership: Direct
Footnotes: F1, F2, F4

ALLK transaction

Common Stock, $0.001 par value

Disposed to Issuer

Transaction value
Shares: -855,211
Change %: -100%
Price
Shares after: 0
Date: 15 May 2025
Ownership: Direct
Footnotes: F1, F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

BVF PARTNERS L P/IL is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

Footnote F2

Represents securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. in exchange for $0.33 in cash per share of Common Stock.

Footnote F3

Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

Footnote F4

Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

Footnote F5

Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.